{
  "docId": "019de073-f0bf-7547-8ad6-12100ed22e83",
  "docSlug": "a88a01f7711a3a01e2c4b1dc80e80f39",
  "documentTitle": "BenevolentAI | Investor Conference Presentation Deck | 17 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 17,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a split-layout: left side defines the disease burden and market opportunity, right side defines the drug mechanism and target patient population.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-f0bf-7547-8ad6-12100ed22e83/12",
  "deckHref": "/decks/019de073-f0bf-7547-8ad6-12100ed22e83",
  "deckJsonHref": "/decks/019de073-f0bf-7547-8ad6-12100ed22e83.json",
  "deckAnchorHref": "/decks/019de073-f0bf-7547-8ad6-12100ed22e83#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.5,
        "y": 0.18
      },
      "kind": "callout",
      "text": "BEN-2293: Topical best-in-class PanTrk inhibitor to relieve inflammation and rapidly resolve itch in patients with AD",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97030800-1097-464c-bd95-b8fa0ed91989",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "Atopic dermatitis is the most common chronic inflammatory skin disease... Affects 10-20% of children... 60-70% of cases... market value to exceed $14 billion",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6959bf39-6d45-4210-8d19-235c5aaf44eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.5,
        "y": 0.3
      },
      "kind": "list",
      "text": "BEN-2293 is a PanTrk inhibitor... expected to treat atopic dermatitis by inhibiting itch signaling... will target Mild, Moderate and Severe Atopic Dermatitis patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1d578b6-deee-4acf-a573-aa65f239b919",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Sources: (1) Weidinger et al. Nat Rev Dis Primers 2018; (2) GlobalData Report 2018... (4) Evaluate Pharma",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "efac807b-93cc-48cc-be0c-c635ac88f9b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "BEN-2293 - Atopic Dermatitis (AD)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf954a23-d38a-46e0-862d-757a9d6ea2f6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 17,
      "from": 9,
      "beatId": "992080ec-aa6d-4a45-852f-5530c22dd391",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 9-17 provide relief, highlighting the validation and potential of BenevolentAI's platform, as well as its business model and future prospects.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 12,
      "from": 9,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "19fab5b9-e3e3-4fbb-b33b-153e51cd2eef",
      "evidence": "The document showcases the validation and potential of BenevolentAI's platform, highlighting its ability to deliver quick wins and support big bets in pharma R&D.",
      "position": 1,
      "objective": "What are the potential benefits of BenevolentAI's platform?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}